Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The substance is considered to have LD50 > 2000 mg/kg bw on acute oral as well as dermal administration.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reason / purpose for cross-reference:
- read-across source
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No deaths occurred during the study.
- Clinical signs:
- Slightly ruffled fur was noted in all animals at the 2-hour reading and persisted in four out of six animals at the 3-hour reading. Hunched posture was also noted in two animals at the 2- and 3-hour reading.
- Body weight:
- The body weight of the animals was within the range commonly recorded for this strain and
age. - Gross pathology:
- No macroscopic findings were observed at necropsy.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- FAT 41048 is considered to have an oral LD50 >2000 mg/kg body weight.
- Executive summary:
Currently no study to assess acute toxicity of FAT 41048 on oral exposure is available.
However, structural analogue FAT 41039/A was evaluated for acute oral toxicity in a study conducted according to OECD Guideline 401 and EU Method B.1. Two groups, each of three female HanRcc:WIST (SPF) rats, were treated with FAT 41039/A by oral gavage administration at a dosage of 2000 mg/kg body weight. The test item was diluted in vehicle PEG 300) at a concentration of 0.2 g/mL and administered at a volume dosage of 10 mL/kg. The animals were examined daily during the acclimatization period and mortality, viability and clinical signs were recorded. All animals were examined for clinical signs at approximately 30 minutes, 1, 2, 3 and 5 hours after treatment on day 1 and once daily during test days 2-15. Mortality/viability was recorded at approximately 30 minutes, 1, 2, 3 and 5 hours after administration on test day 1 (with the clinical signs) and twice daily during days 2-15. Body weights were recorded on day 1 (prior to administration) and on days 8 and 15. All animals were necropsied and examined macroscopically.
All animals survived until the end of the study period. Slightly ruffled fur was noted in all animals at the 2-hour reading and persisted in four out of six animals at the 3-hour reading. Hunched posture was also noted in two animals at the 2 - and 3-hour reading. Orange feces were noted in the cages of both groups on test day 2. The body weight of the animals was within the range commonly recorded for this strain andage. No macroscopic findings were recorded at necropsy. Hence, based on the findings of the study, the median lethal dose of FAT 41039/A after single oral administration to female rats, observed over a period of 14 days was >2000 mg/kg body weight.
Using the principles of read across, FAT 41048 is also considered to have an oral LD50 >2000 mg/kg body weight.
Reference
None
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- High quality GLP study
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reason / purpose for cross-reference:
- read-across source
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No deaths occurred during the study.
- Clinical signs:
- No clinical signs were observed during the course of the study. Orange discoloration of the treated skin area produced by the test item prevent the assessment of a possible erythema in all animals on test day 2 and in one male animal on test day 3.
- Body weight:
- The body weight of the animals was within the range commonly recorded for this strain and age.
- Gross pathology:
- No macroscopic findings were observed at necropsy.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- FAT 41048 is also considered to have dermal LD50 >2000 mg/kg body weight.
- Executive summary:
Currently no study to assess acute toxicity on dermal exposure of FAT 41048 is available. However, structural analogue, FAT 41039/A was evaluated for acute dermal toxicity in a study conducted according to OECD Guideline 402 and EU Method B.3. Five male and five female HanRcc.WIST (SPF) rats were treated with FAT 41039/A at 2000 mg/kg by dermal application. The test item was diluted in vehicle (PEG 300) at a concentration of 0.33 g/mL and administered at a volume dosage of 6 mL/kg. The application period was 24 hours. The animals were examined daily during the acclimatization period and mortality, viability and clinical signs were recorded. All animals were examined for clinical signs at approximately 30 minutes, 1, 2, 3 and 5 hours after treatment on day 1 and once daily during test days 2-15. Local signs were noted once daily from test day 2 to 15. Mortality/viability was recorded at approximately 30 minutes, 1,2,3 and 5 hours after administration on test day 1 (with the clinical signs) and twice daily during days 2-15. Body weights were recorded on day 1 (prior to administration) and on days 8 and 15. All animals were necropsied and examined macroscopically.
No deaths or clinical signs were observed during the course of the study. The body weight of the animals was within the range commonly recorded for this strain and age. No macroscopic findings were observed at necropsy. Hence, based on the findings of the study, the median lethal dose (LD50) of FAT 41039/A after single dermal administration to rats of both sexes, observed over a period of 14 days was >2000 mg/kg body weight.
Using the principles of read across, FAT 41048 is also considered to have dermal LD50 >2000 mg/kg body weight.
Reference
None
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- HIgh quality GLP study
Additional information
Oral:
Currently no study to assess acute toxicity of FAT 41048 on oral exposure is available. However, structural analogue FAT 41039/A was evaluated for acute oral toxicity in a study conducted according to OECD Guideline 401 and EU Method B.1. Two groups, each of three female HanRcc:WIST (SPF) rats, were treated with FAT 41039/A by oral gavage administration at a dosage of 2000 mg/kg body weight. The test item was diluted in vehicle PEG 300) at a concentration of 0.2 g/mL and administered at a volume dosage of 10 mL/kg. The animals were examined daily during the acclimatization period and mortality, viability and clinical signs were recorded. All animals were examined for clinical signs at approximately 30 minutes, 1, 2, 3 and 5 hours after treatment on day 1 and once daily during test days 2-15. Mortality/viability was recorded at approximately 30 minutes, 1, 2, 3 and 5 hours after administration on test day 1 (with the clinical signs) and twice daily during days 2-15. Body weights were recorded on day 1 (prior to administration) and on days 8 and 15. All animals were necropsied and examined macroscopically.
All animals survived until the end of the study period. Slightly ruffled fur was noted in all animals at the 2-hour reading and persisted in four out of six animals at the 3-hour reading. Hunched posture was also noted in two animals at the 2 - and 3-hour reading. Orange feces were noted in the cages of both groups on test day 2. The body weight of the animals was within the range commonly recorded for this strain andage. No macroscopic findings were recorded at necropsy. Hence, based on the findings of the study, the median lethal dose of FAT 41039/A after single oral administration to female rats, observed over a period of 14 days was >2000 mg/kg body weight.
Using the principles of read across, FAT 41048 is also considered to have an oral LD50 >2000 mg/kg body weight.
Inhalation:
Currently no study to assess the acute inhalation toxicity potential of FAT 41048 is available. Poor water solubility and moderate partition coefficient values indicate that both chemicals may favour absorption across the respiratory tract epithelium by passive diffusion. However, owing to the high melting points (>300 °C), both chemicals can be considered to have low volatility and hence exposure through respiration is regarded to be low.Nevertheless, the use of this substance and the related products are not expected to result in aerosols, particles or droplets of an inhalable size, so exposure to humans via the inhalation route will be unlikely to occur. Further, no systemic effects or mortality were observed in the acute oral and acute dermal toxicity studies with FAT 41039. Taking into consideration above information, acute inhalation exposure is considered to have negligible potential for systemic toxicity.
Dermal:
Currently no study to assess acute toxicity on dermal exposure of FAT 41048 is available. However, structural analogue, FAT 41039/A was evaluated for acute dermal toxicity in a study conducted according to OECD Guideline 402 and EU Method B.3. Five male and five female HanRcc.WIST (SPF) rats were treated with FAT 41039/A at 2000 mg/kg body weight by dermal application. The test item was diluted in vehicle (PEG 300) at a concentration of 0.33 g/mL and administered at a volume dosage of 6 mL/kg. The application period was 24 hours. The animals were examined daily during the acclimatization period and mortality, viability and clinical signs were recorded. All animals were examined for clinical signs at approximately 30 minutes, 1, 2, 3 and 5 hours after treatment on day 1 and once daily during test days 2-15. Local signs were noted once daily from test day 2 to 15. Mortality/viability was recorded at approximately 30 minutes, 1, 2, 3 and 5 hours after administration on test day 1 (with the clinical signs) and twice daily during days 2-15. Body weights were recorded on day 1 (prior to administration) and on days 8 and 15. All animals were necropsied and examined macroscopically.
No deaths or clinical signs were observed during the course of the study. The body weight of the animals was within the range commonly recorded for this strain and age. No macroscopic findings were observed at necropsy. Hence, based on the findings of the study, the median lethal dose (LD50) of FAT 41039/A after single dermal administration to rats of both sexes, observed over a period of 14 days was >2000 mg/kg body weight.
Using the principles of read across, FAT 41048 is also considered to have dermal LD50 >2000 mg/kg body weight.
Justification for classification or non-classification
The substance is considered to have LD50 >2000 mg/kg bw on acute oral as well as dermal administration, hence does not warrant classification according to Regulation (EC) No. 1272/2008 (CLP) criteria.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.